Exact Mass: 679.3123

Exact Mass Matches: 679.3123

Found 70 metabolites which its exact mass value is equals to given mass value 679.3123, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

   

Thiazinotrienomycin G

Thiazinotrienomycin G

C37H49N3O7S (679.3291)


   
   

8-Deoxyrifamycin S

8-Deoxyrifamycin S

C37H45NO11 (679.2992)


   
   
   

1beta-cis-cinnamoyl-4alpha-hydroxy-5alpha,7beta,11-triacetoxy-8beta-nicotinoyldihydroagarofuran|triptersinine E

1beta-cis-cinnamoyl-4alpha-hydroxy-5alpha,7beta,11-triacetoxy-8beta-nicotinoyldihydroagarofuran|triptersinine E

C36H41NO12 (679.2629)


   

Me ester-Pimaricin

Me ester-Pimaricin

C34H49NO13 (679.3204)


   

Gln Arg Val Met Phe

Gln Arg Val Met Phe

C30H49N9O7S (679.3475)


   

His Ala Tyr Tyr Leu

His Ala Tyr Tyr Leu

C34H45N7O8 (679.3329)


   

Arg Arg Trp Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H45N11O6 (679.3554)


   

Arg Arg Tyr Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H45N11O6 (679.3554)


   

Arg Trp Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H45N11O6 (679.3554)


   

Arg Trp Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C32H45N11O6 (679.3554)


   

Arg Tyr Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C32H45N11O6 (679.3554)


   

Arg Tyr Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H45N11O6 (679.3554)


   

Trp Arg Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C32H45N11O6 (679.3554)


   

Trp Arg Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C32H45N11O6 (679.3554)


   

Trp Tyr Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C32H45N11O6 (679.3554)


   

Tyr Arg Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C32H45N11O6 (679.3554)


   

Tyr Arg Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C32H45N11O6 (679.3554)


   

Tyr Trp Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C32H45N11O6 (679.3554)


   

QRVMF

Gln-Arg-Val-Met-Phe

C30H49N9O7S (679.3475)


   

OHHdiA-PS

1-(9Z-octadecenoyl)-2-(4-hydroxy-6-carboxy-5E-hexenoyl)-sn-glycero-3-phosphoserine

C31H54NO13P (679.3333)


   

dihydroergotamine mesylate

Dihydro Ergotamine Mesylate

C34H41N5O8S (679.2676)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents D002491 - Central Nervous System Agents > D000700 - Analgesics Dihydroergotamine mesylate is an ergot alkaloid that can be used for the research of migraines[1][2][3].

   

Ac-Val-Asp-Val-Ala-Asp-pNA

Ac-Val-Asp-Val-Ala-Asp-pNA

C29H41N7O12 (679.2813)


   

1-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea

1-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea

C34H48F3N5O6 (679.3557)


   

1-[[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea

1-[[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea

C34H48F3N5O6 (679.3557)


   

5-methoxycarbonylpentyl 4,6-dideoxy-4-formamido-2-O-methyl-alpha-D-mannopyranosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannopyranosyl-(1->3)-4,6-dideoxy-4-formamido-alpha-D-mannopyranoside

5-methoxycarbonylpentyl 4,6-dideoxy-4-formamido-2-O-methyl-alpha-D-mannopyranosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannopyranosyl-(1->3)-4,6-dideoxy-4-formamido-alpha-D-mannopyranoside

C29H49N3O15 (679.3164)


   
   
   
   
   
   

SHexCer 10:1;2O/16:2;O

SHexCer 10:1;2O/16:2;O

C32H57NO12S (679.3601)


   

SHexCer 13:2;2O/13:1;O

SHexCer 13:2;2O/13:1;O

C32H57NO12S (679.3601)


   

SHexCer 12:2;2O/14:1;O

SHexCer 12:2;2O/14:1;O

C32H57NO12S (679.3601)


   

SHexCer 14:3;2O/12:0;O

SHexCer 14:3;2O/12:0;O

C32H57NO12S (679.3601)


   

SHexCer 14:2;2O/12:1;O

SHexCer 14:2;2O/12:1;O

C32H57NO12S (679.3601)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

ST 26:5;O8;HexNAc

ST 26:5;O8;HexNAc

C34H49NO13 (679.3204)


   

ST 27:4;O7;HexNAc

ST 27:4;O7;HexNAc

C35H53NO12 (679.3568)


   

Fibrinogen-Binding Peptide (TFA)

Fibrinogen-Binding Peptide (TFA)

C27H40F3N7O10 (679.2789)


Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin[1].

   

n-(1-oxo-1-{[(8e,10e,16z)-3,15,27-trihydroxy-5-methoxy-14,16-dimethyl-22-thia-2,24-diazatricyclo[18.6.1.0²¹,²⁵]heptacosa-1(27),2,6,8,10,16,20,23,25-nonaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

n-(1-oxo-1-{[(8e,10e,16z)-3,15,27-trihydroxy-5-methoxy-14,16-dimethyl-22-thia-2,24-diazatricyclo[18.6.1.0²¹,²⁵]heptacosa-1(27),2,6,8,10,16,20,23,25-nonaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

C37H49N3O7S (679.3291)


   

(1s,3r,5r,7s,8e,14e,16e,18e,20e,22s,24r,25s,26r)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

(1s,3r,5r,7s,8e,14e,16e,18e,20e,22s,24r,25s,26r)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

C34H49NO13 (679.3204)


   

22-[(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy]-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

22-[(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy]-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

C34H49NO13 (679.3204)


   

(1r,2s,3s,7s,10r,13r,14s,15r,17r,18r,19r)-8,15,17,18-tetrahydroxy-7-(2-methanesulfinylethyl)-3,19-dimethoxy-2,14,18-trimethyl-10-(2-methylpropyl)-13-propyl-6,12,21-trioxa-9-azabicyclo[15.3.1]henicos-8-ene-5,11-dione

(1r,2s,3s,7s,10r,13r,14s,15r,17r,18r,19r)-8,15,17,18-tetrahydroxy-7-(2-methanesulfinylethyl)-3,19-dimethoxy-2,14,18-trimethyl-10-(2-methylpropyl)-13-propyl-6,12,21-trioxa-9-azabicyclo[15.3.1]henicos-8-ene-5,11-dione

C32H57NO12S (679.3601)


   

(1r,3s,5r,7r,8e,12r,13s,14e,16e,18e,20e,22r,24s,25r,26s)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

(1r,3s,5r,7r,8e,12r,13s,14e,16e,18e,20e,22r,24s,25r,26s)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

C34H49NO13 (679.3204)


   

2-[2-(6-{[(3r,4ar,8s,11r,14s)-3,9,12-trihydroxy-14-methyl-11-(2-methylpropyl)-5,15-dioxo-1h,2h,3h,4h,4ah,7h,8h,11h,14h-pyridazino[3,2-c]1-oxa-4,7,10-triazacyclotridecan-8-yl]-c-hydroxycarbonimidoyl}-5,6-dihydro-4h-pyridazin-1-yl)-2-oxoethyl]heptanoic acid

2-[2-(6-{[(3r,4ar,8s,11r,14s)-3,9,12-trihydroxy-14-methyl-11-(2-methylpropyl)-5,15-dioxo-1h,2h,3h,4h,4ah,7h,8h,11h,14h-pyridazino[3,2-c]1-oxa-4,7,10-triazacyclotridecan-8-yl]-c-hydroxycarbonimidoyl}-5,6-dihydro-4h-pyridazin-1-yl)-2-oxoethyl]heptanoic acid

C31H49N7O10 (679.3541)


   

n-[(2r,3s,4s,5s,6r)-6-{[(1s,5r,7e,9r,10r,11s,12s,13s)-5-[(1e,3e)-6-[(1r,2s)-2-chlorocyclopropyl]hexa-1,3-dien-5-yn-1-yl]-1-hydroxy-9-methoxy-7,10,12-trimethyl-3-oxo-4,15-dioxabicyclo[9.3.1]pentadec-7-en-13-yl]oxy}-4-hydroxy-5-methoxy-2,4-dimethyloxan-3-yl]carboximidic acid

n-[(2r,3s,4s,5s,6r)-6-{[(1s,5r,7e,9r,10r,11s,12s,13s)-5-[(1e,3e)-6-[(1r,2s)-2-chlorocyclopropyl]hexa-1,3-dien-5-yn-1-yl]-1-hydroxy-9-methoxy-7,10,12-trimethyl-3-oxo-4,15-dioxabicyclo[9.3.1]pentadec-7-en-13-yl]oxy}-4-hydroxy-5-methoxy-2,4-dimethyloxan-3-yl]carboximidic acid

C35H50ClNO10 (679.3123)


   

2-[2-(6-{[(4ar,8s,11r,14s)-9,12-dihydroxy-14-methyl-11-(2-methylpropyl)-5,15-dioxo-1h,2h,3h,4h,4ah,7h,8h,11h,14h-pyridazino[3,2-c]1-oxa-4,7,10-triazacyclotridecan-8-yl]-c-hydroxycarbonimidoyl}-5,6-dihydro-4h-pyridazin-1-yl)-2-oxoethyl]-6-hydroxyheptanoic acid

2-[2-(6-{[(4ar,8s,11r,14s)-9,12-dihydroxy-14-methyl-11-(2-methylpropyl)-5,15-dioxo-1h,2h,3h,4h,4ah,7h,8h,11h,14h-pyridazino[3,2-c]1-oxa-4,7,10-triazacyclotridecan-8-yl]-c-hydroxycarbonimidoyl}-5,6-dihydro-4h-pyridazin-1-yl)-2-oxoethyl]-6-hydroxyheptanoic acid

C31H49N7O10 (679.3541)


   

2-(2,3-dimethyloxiran-2-yl)-5,11-dihydroxy-10-{5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4,6-dimethyl-4-(methylamino)oxan-2-yl}-1-oxatetraphene-4,7,12-trione

2-(2,3-dimethyloxiran-2-yl)-5,11-dihydroxy-10-{5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4,6-dimethyl-4-(methylamino)oxan-2-yl}-1-oxatetraphene-4,7,12-trione

C36H41NO12 (679.2629)